Table 2 Performance of the 95-gene residual risk signature and multiparametric tests in the validation cohort
From: Molecular stratification of early breast cancer identifies drug targets to drive stratified medicine
HR | HR.95L | HR.95U | P | N | AUC | |
|---|---|---|---|---|---|---|
95-Gene Signature | 5.045 | 3.528 | 7.215 | 7.51 × 10−19 | 1924 | 0.76 |
MammaPrint-like | 3.631 | 2.765 | 4.767 | 1.66 × 10−20 | 1973 | 0.72 |
Prosigna-like | 3.49 | 2.592 | 4.699 | 1.75 × 10−16 | 1971 | 0.70 |
IHC4-RNA | 3.475 | 2.346 | 5.148 | 5.11 × 10−10 | 1973 | 0.72 |
Genomic Grade Index-like | 3.118 | 2.341 | 4.153 | 7.51 × 10−15 | 1973 | 0.67 |
OncotypeDX-like | 2.969 | 2.232 | 3.948 | 7.37 × 10−14 | 1973 | 0.71 |
IHC4-Protein | 2.398 | 1.851 | 3.108 | 3.72 × 10−11 | 1855 | 0.68 |
